Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...
CLOSURE-AF and CREST-2 were widely read, but stories on GLP-1s, DOACs in AF, and a new PCSK9 inhibitor were popular, too.
The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback